Colorectal carcinoma (CRC) · line 1 · FOLFOXIRI + Bevacizumab

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Line of therapy	1
Track	aggressive
Linked regimen	`REG-FOLFOXIRI-BEV`

ID	`IND-CRC-METASTATIC-1L-FOLFOXIRI-BEV`
Type	Indication
Status	reviewed 2026-05-03 \| pending_clinical_signoff
Diseases	`DIS-CRC`
Sources	`SRC-ESMO-COLON-2024` `SRC-NCCN-COLON-2025` `SRC-TRIBE-LOUPAKIS-2014` `SRC-TRIBE2-CREMOLINI-2020`

Notes

Reserve for fit patients (ECOG 0-1, ideally <75) with high-burden mCRC where maximal response matters (BRAF V600E, conversion intent, symptomatic high-volume disease). Plan de-escalation to maintenance (bev ± capecitabine) after 4-6 months induction to limit cumulative neuropathy and fatigue.

Used By

Algorithms

ALGO-CRC-METASTATIC-1L - ALGO-CRC-METASTATIC-1L

Handbook Chapters

HB-CRC-METASTATIC-1L - Metastatic colorectal cancer: first-line biomarker reasoning